Primary prevention of coronary heart disease in women

Menopause International

Volumn 14, Issue 1, 2008, Pages 40-45

  Rees, Margaret ^a   Stevenson, John ^b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Cardiovascular disease; Coronary heart disease; Postreproductive health; Prevention; Women

Indexed keywords

26 HYDROXYCHOLESTEROL; ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ASCORBIC ACID; CALCIUM CARBONATE; COLESTIPOL; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DOCOSAHEXAENOIC ACID; DROSPIRENONE PLUS ESTRADIOL; FENOFIBRATE; FOLIC ACID; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; ANTITHROMBOCYTIC AGENT;

CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIET SUPPLEMENTATION; DIET THERAPY; DRUG CLEARANCE; EARLY MENOPAUSE; ESTROGEN THERAPY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; POSTMENOPAUSE; PRIMARY PREVENTION; SMOKING CESSATION; VERTEBRA FRACTURE; AGED; CONSENSUS DEVELOPMENT; CORONARY ARTERY DISEASE; DIET; FEMALE; MIDDLE AGED; RISK REDUCTION;

AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CORONARY DISEASE; DIET; DIETARY SUPPLEMENTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTMENOPAUSE; RISK REDUCTION BEHAVIOR; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 47249140849     PISSN: 13621807     EISSN: 17404568     Source Type: Journal    
DOI: 10.1258/mi.2007.007037     Document Type: Conference Paper

References (73)

1. British Heart Foundation. See http://www.heartstats.org (accessed 26 November 2007)
2. Stevenson JC. HRT and the primary prevention of cardiovascular disease. Maturitas 2007;57:31-34 (Pubitemid 46602887)
3. Rossouw JE, Anderson GL, Prentice RL. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333 (Pubitemid 34761611)
4. Manson JE, Hsia J, Johnson KC, et al. Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534
5. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712
6. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease. Arch Intern Med 2006;166:357-365
7. Prentice RL, Langer RD, Stefanick ML, et al. Combined analysis of Women's Health Initiative Observational and Clinical Trial Data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol 2006;163:589-599
8. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477 (Pubitemid 46556472)
9. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44 (Pubitemid 43192860)
10. Manson JE, Allison MA, Rossouw JE, et al. WHI and WHI-CACS investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602
11. Umetani M, Domoto H, Gormley AK, et al. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat Med 2007;13:1185-1192 (Pubitemid 47530633)
12. Collins P, Rosano GM, Sarrel PM, et al. 17 b-Estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30
13. Lobo RA. Surgical menopause and cardiovascular risks. Menopause 2007;14 (3 suppl):562-566
14. Lokkegaard E, Jovanovic Z, Heitmann BL, et al. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 2006;53:226-233 (Pubitemid 41820516)
15. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007;115:1481-1501
16. NCEP Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-2497
17. Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004;291:2243-2252
18. Hodis HN, Mack WJ. Postmenopausal hormone therapy in clinical perspective. Menopause 2007;14:1-14 (Pubitemid 47517597)
19. Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006;60:442-449
20. Keech A, Simes RJ, Barter P, et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-1861
21. ACCORD. See http://www.accordtrial.org/public/index.cfm (accessed 26 November 2007)
22. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114 (Pubitemid 41025967)
23. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-172
24. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304 (Pubitemid 40411496)
25. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313 (Pubitemid 43112959)
26. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J 2005;26:1585-1595 (Pubitemid 41389688)
27. Becker DM, Segal J, Vaidya D, et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006;295:1420-1427
28. Lewington S, Clarke R, Qizilbash N, et al. Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913
29. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206
30. van der Giezen AM, Schopman-Geurts, van Kessel JG, et al. Systolic blood pressure and cardiovascular mortality among 13,740 Dutch women. Prev Med 1990;19:456-465 (Pubitemid 20261190)
31. National Heart and Lung Blood Institute. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Complete report 2004. See http:// www.nhlbi.nih.gov/guidelines/ hypertension/jnc7full.htm (accessed 26 November 2007)
32. Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12:716-727 (Pubitemid 41669124)
33. Forouhi NG, Merrick D, Goyder E, et al. Diabetes prevalence in England, 2001 - estimates from an epidemiological model. Diabet Med 2006;23:189-197
34. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2002;162:1737-1745 (Pubitemid 34894803)
35. Buchanan TA, Xiang AH, Peters RK, et al. The TRIPOD study: preservation of pancreatic B-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. Diabetes 2002;51:2796-2803 (Pubitemid 34970933)
36. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-1136 (Pubitemid 47464583)
37. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
38. Bonds DE, Lasser N, Qi L, et al. The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. Diabetologia 2006;49:459-468 (Pubitemid 43277868)
39. Kanaya AM, Herrington D, Vittinghoff E, et al. Heart and estrogen/ progestin replacement study. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9
40. Sobel BE. Optimizing cardiovascular outcomes in diabetes mellitus. Am J Med 2007;120(9 Suppl 2):S3-11 (Pubitemid 47361037)
41. Patel A, ADVANCE Collaborative Group, MacMahon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-840 (Pubitemid 47362321)
42. Riche DM, McClendon KS. Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2007;64:1603-1610 (Pubitemid 47173538)
43. Bentley-Lewis R, Koruda K, Seely EW. The metabolic syndrome in women. Nat Clin Pract Endocrinol Metab 2007;3:696-704
44. Spencer CP, Godsland IF, Stevenson JC. Is there a menopausal metabolic syndrome? Gynecol Endocrinol 1997;11:341-355
45. Stampfer MJ, Hu FB, Manson JE, et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000;343:16-22 (Pubitemid 30447987)
46. Mann JI. Nutrition recommendations for the treatment and prevention of type 2 diabetes and the metabolic syndrome: an evidenced-based review. Nutr Rev 2006;64:422-427 (Pubitemid 44525201)
47. Palacios S. The future of the new selective estrogen receptor modulators. Menopause Int 2007;13:27-34 (Pubitemid 46692067)
48. Barrett-Connor E, Mosca L, Collins P, et al. Raloxifene Use for The Heart (RUTH) trial investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-137
49. Dauchet L, Amouyel P, Hercberg S, Dallongeville J. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J Nutr 2006;136:2588-2593 (Pubitemid 44521618)
50. Howard BV, Van Horn L, Hsia J, et al. Low-fat dietary pattern and risk of cardiovascular disease. JAMA 2006;295:655-666
51. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the women's health study: a randomized controlled trial. JAMA 2005;294:56-65 (Pubitemid 41002839)
52. Lonn E, Bosch J, Yusuf S, et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. A randomized controlled trial. JAMA 2005;293:1338-1347
53. Miller IIIE, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2004;142:1-11 (Pubitemid 40066212)
54. Lee DH, Folsom AR, Harnack L, et al. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 2004;80:1194-1200
55. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-2440 (Pubitemid 35340539)
56. Hsia J, Heiss G, Ren H, et al. Women's health initiative investigators. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115:846-854
57. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006;333:1114-1117 (Pubitemid 44863652)
58. Din JN, Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease - fishing for a natural treatment. BMJ 2004;328:30-35 (Pubitemid 38067742)
59. Jacobson TA. Beyond lipids: the role of omega-3 fatty acids from fish oil in the prevention of coronary heart disease. Curr Atheroscler Rep 2007;9:145-153 (Pubitemid 47381173)
60. Jarvinen R, Knekt P, Rissanen H, Reunanen A. Intake of fish and long-chain n-3 fatty acids and the risk of coronary heart mortality in men and women. Br J Nutr 2006;95:824-829
61. Manson JE, Willet WC, Stampfer MJ, et al. Body weight and mortality among women. N Engl J Med 1995;333:677-685
62. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA 1998;280:1843-1848 (Pubitemid 28544425)
63. Yarnell JW, Patterson CC, Thomas HF, et al. Central obesity: predictive value of skinfold measurements for subsequent ischaemic heart disease at 14 years follow-up in the Caerphilly Study. Int J Obes Relat Metab Disord 2001;25:1546-1549 (Pubitemid 32977875)
64. National Institute of Health and Clinical Excellence. Obesity: the prevention, identification, assessment and management of overweight and obesity in adults and children, December 2006. See CG43http:// guidance.nice.org.uk/ CG43/guidance (accessed 26 November 2007)
65. Willett WC. The Mediterranean diet: science and practice. Public Health Nutr 2006;9:105-110
66. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003;348:2599-2608 (Pubitemid 36741587)
67. Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ 1998;316:1043-1047 (Pubitemid 28143100)
68. Allender S, Peto V, Scarborough P, Boxer A, Rayner M. Coronary Heart Disease Statistics 2007. London: British Heath Foundation. See http://www.heartstats.org (accessed 26 November 2007)
69. Yusaf S, Hawken S, Ounpuu S, et al. On behalf of the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART Study): case control study. Lancet 2004;364:937-952
70. Godtfredsen NS, Osler M, Vestbo J, Andersen I, Prescott E. Smoking reduction, smoking cessation, and incidence of fatal and non-fatal myocardial infarction in Denmark 1976-1998: a pooled cohort study. J Epidemiol Community Health 2003;57:412-416
71. Blair SN, Kohl HW, Paffenbarger RS, et al. Physical fitness and all cause mortality: a prospective study of healthy men and women. JAMA 1989;262:2395-2401 (Pubitemid 19261810)
72. Bush TL, Fried LP, Barrett-Connor E. Cholesterol, lipoproteins and coronary heart disease in women. Clin Chem 1988;34:B60-B70 (Pubitemid 18216243)
73. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med 2002;347:716-725 (Pubitemid 35203902)